PMID- 37500145
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 8
DP  - 2023 Aug
TI  - Relationship Between Hematological Toxicities During Maintenance Treatment and 
      During Chemotherapy Before Maintenance Treatment in Patients With 
      Platinum-sensitive Relapsed Ovarian Cancer.
PG  - 3653-3658
LID - 10.21873/anticanres.16546 [doi]
AB  - BACKGROUND/AIM: To determine if maintenance treatment can be performed 
      effectively and safely in patients with platinum-sensitive relapsed ovarian 
      cancer. PATIENTS AND METHODS: We carried out a multi-center study to investigate 
      progression-free survival (PFS) and adverse events (AEs) in 229 patients 
      receiving maintenance treatment for platinum-sensitive relapsed ovarian cancer. 
      RESULTS: The median PFS in the 229 patients with maintenance treatment was 14.0 
      months (95% confidence interval=10.3-17.6 months). The hematological toxicities 
      included >/=grade 3 anemia in 33.2% of cases. Anemia during maintenance treatment 
      was significantly more common than anemia during chemotherapy given before 
      maintenance treatment (p<0.001). Anemia during chemotherapy prior to maintenance 
      treatment significantly increased the risk of anemia during maintenance 
      treatment, compared with other clinical features (p<0.001). CONCLUSION: 
      Maintenance treatment can be performed safely and effectively in patients with 
      platinum-sensitive relapsed ovarian cancer. Anemia during chemotherapy given 
      before maintenance treatment significantly increased the risk of developing 
      anemia during maintenance treatment in patients with platinum-sensitive relapsed 
      ovarian cancer.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Matsuoka, Hirofumi
AU  - Matsuoka H
AD  - Department of Obstetrics and Gynecology, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
FAU - Nakamura, Keiichiro
AU  - Nakamura K
AD  - Department of Obstetrics and Gynecology, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; 
      k-nakamu@cc.okayama-u.ac.jp.
FAU - Yorimitsu, Masae
AU  - Yorimitsu M
AD  - Department of Obstetrics and Gynecology, Hiroshima City Hiroshima Citizens 
      Hospital, Hiroshima, Japan.
FAU - Ogawa, Mariko
AU  - Ogawa M
AD  - Department of Obstetrics and Gynecology, National Organization Fukuyama Medical 
      Center, Hiroshima, Japan.
FAU - Kanemori, Miho
AU  - Kanemori M
AD  - Department of Obstetrics and Gynecology, Fukuyama City Hospital, Hiroshima, 
      Japan.
FAU - Sueoka, Kotaro
AU  - Sueoka K
AD  - Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of 
      Medicine, Yamaguchi, Japan.
FAU - Kozai, Ayumi
AU  - Kozai A
AD  - Department of Perinatology and Gynecology, Kagawa University Graduate School of 
      Medicine, Kagawa, Japan.
FAU - Nakamura, Hiroko
AU  - Nakamura H
AD  - Department of Obstetrics and Gynecology, National Hospital Organization KURE 
      Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
FAU - Haruma, Tomoko
AU  - Haruma T
AD  - Department of Obstetrics and Gynecology, Okayama Saiseikai General Hospital, 
      Okayama, Japan.
FAU - Shiroyama, Yuko
AU  - Shiroyama Y
AD  - Department of Obstetrics and Gynecology, Hiroshima Prefectural Hospital, 
      Hiroshima, Japan.
FAU - Hayata, Yuu
AU  - Hayata Y
AD  - Department of Obstetrics and Gynecology, Kagawa Prefectural Central Hospital, 
      Kagawa, Japan.
FAU - Sugii, Hirokazu
AU  - Sugii H
AD  - Department of Obstetrics and Gynecology, National Hospital Organization Iwakuni 
      Clinical Center, Yamaguchi, Japan.
FAU - Ueda, Akiko
AU  - Ueda A
AD  - Department of Obstetrics and Gynecology, JA Onomichi General Hospital, Hiroshima, 
      Japan.
FAU - Kurihara, Shuichi
AU  - Kurihara S
AD  - Department of Obstetrics and Gynecology, Japanese Red Cross Matsuyama Hospital, 
      Ehime, Japan.
FAU - Urayama, Saiko
AU  - Urayama S
AD  - Higashihiroshima Medical Center, Hiroshima, Japan.
FAU - Shimizu, Miyuki
AU  - Shimizu M
AD  - Kagawa Rosai Hospital, Kagawa, Japan.
FAU - Masuyama, Hisashi
AU  - Masuyama H
AD  - Department of Obstetrics and Gynecology, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Humans
MH  - Female
MH  - *Ovarian Neoplasms/drug therapy
MH  - Carcinoma, Ovarian Epithelial/drug therapy
MH  - Progression-Free Survival
MH  - *Anemia/chemically induced
MH  - Neoplasm Recurrence, Local
MH  - Maintenance Chemotherapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
OTO - NOTNLM
OT  - Maintenance treatment
OT  - anemia
OT  - chemotherapy before maintenance treatment
OT  - platinum-sensitive relapsed ovarian cancer
EDAT- 2023/07/28 01:08
MHDA- 2023/07/31 06:42
CRDT- 2023/07/27 20:43
PHST- 2023/06/02 00:00 [received]
PHST- 2023/06/27 00:00 [revised]
PHST- 2023/06/28 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/07/28 01:08 [pubmed]
PHST- 2023/07/27 20:43 [entrez]
AID - 43/8/3653 [pii]
AID - 10.21873/anticanres.16546 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Aug;43(8):3653-3658. doi: 10.21873/anticanres.16546.